Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

varlitinib tosylate

The tosylate salt form of varlitinib, an orally bioavailable inhibitor of the epidermal growth factor receptor family with potential antineoplastic activity. Varlitinib selectively and reversibly binds to both EGFR (ErbB-1) and Her-2/neu (ErbB-2) and prevents their phosphorylation and activation, which may result in inhibition of the associated signal transduction pathways, inhibition of cellular proliferation and cell death. EGFR and Her-2 play important roles in cell proliferation and differentiation and are upregulated in various human tumor cell types. Due to the dual inhibition of both EGFR and Her-2, this agent may be therapeutically more effective than agents that inhibit EGFR or Her-2 alone.
Code name:AR00334543 ditosilate
AR00334543 ditosylate
ARRY-334543 ditosylate
ARRY-543 ditosilate
ARRY-543 ditosylate
Chemical structure:4-N-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-6-N-((4r)-4-methyl-4,5-dihydrooxazol-2- Yl)quinazoline-4,6-diamine bis(4-methylbenzenesulphonate)
4,6-quinazolinediamine, N(sup 4)-(3-chloro-4-(2-thiazolylmethoxy)phenyl)-N(sup 6)-((4r)-4,5-dihydro-4-methyl-2-oxazolyl)-, 4-methylbenzenesulphonate (1:2)
Search NCI's Drug Dictionary